Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
Saved in:
| Title: | Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. |
|---|---|
| Authors: | Matulonis, Ursula A.1 (AUTHOR) ursula_matulonis@dfci.harvard.edu, Vergote, Ignace2 (AUTHOR), Moore, Kathleen N.3 (AUTHOR), Martin, Lainie P.4 (AUTHOR), Castro, Cesar M.5 (AUTHOR), Gilbert, Lucy6,7,8 (AUTHOR), Xia, Yu9 (AUTHOR), Method, Michael10 (AUTHOR), Stec, James10 (AUTHOR), Birrer, Michael J.11 (AUTHOR), O'Malley, David M.12 (AUTHOR) |
| Source: | Gynecologic Oncology. Sep2025, Vol. 200, p96-104. 9p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
